Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 170

1.

Cerebral white matter structure is associated with DSM-5 schizophrenia symptom dimensions.

Viher PV, Stegmayer K, Giezendanner S, Federspiel A, Bohlhalter S, Vanbellingen T, Wiest R, Strik W, Walther S.

Neuroimage Clin. 2016 Jun 16;12:93-99. eCollection 2016.

2.

The association between antibodies to neurotropic pathogens and schizophrenia: a case-control study.

de Witte LD, van Mierlo HC, Litjens M, Klein HC, Bahn S, Osterhaus AD; GROUP Investigators.

NPJ Schizophr. 2015 Nov 4;1:15041. doi: 10.1038/npjschz.2015.41. eCollection 2015.

3.

The prevalence of antinuclear antibodies in patients with schizophrenia spectrum disorders: results from a large cohort study.

van Mierlo HC, de Witte L, Derksen RH, Otten HG; GROUP investigators.

NPJ Schizophr. 2015 May 6;1:15013. doi: 10.1038/npjschz.2015.13. eCollection 2015.

4.

Reduced fronto-striatal white matter integrity in schizophrenia patients and unaffected siblings: a DTI study.

de Leeuw M, Bohlken MM, Mandl RC, Kahn RS, Vink M.

NPJ Schizophr. 2015 Apr 1;1:15001. doi: 10.1038/npjschz.2015.1. eCollection 2015.

5.

Deficits in Degraded Facial Affect Labeling in Schizophrenia and Borderline Personality Disorder.

van Dijke A, van 't Wout M, Ford JD, Aleman A.

PLoS One. 2016 Jun 14;11(6):e0154145. doi: 10.1371/journal.pone.0154145. eCollection 2016.

6.

Mentalization-based treatment for psychotic disorder: protocol of a randomized controlled trial.

Weijers J, Ten Kate C, Eurelings-Bontekoe E, Viechtbauer W, Rampaart R, Bateman A, Selten JP.

BMC Psychiatry. 2016 Jun 8;16:191. doi: 10.1186/s12888-016-0902-x.

7.

Evidence for Trait Related Theory of Mind Impairment in First Episode Psychosis Patients and Its Relationship with Processing Speed: A 3 Year Follow-up Study.

Ayesa-Arriola R, Setién-Suero E, Neergaard KD, Ferro A, Fatjó-Vilas M, Ríos-Lago M, Otero S, Rodríguez-Sánchez JM, Crespo-Facorro B.

Front Psychol. 2016 May 4;7:592. doi: 10.3389/fpsyg.2016.00592. eCollection 2016.

8.

Cognitive Performance and Long-Term Social Functioning in Psychotic Disorder: A Three-Year Follow-Up Study.

Simons CJ, Bartels-Velthuis AA, Pijnenborg GH; Genetic Risk and Outcome of Psychosis (GROUP) Investigators.

PLoS One. 2016 Apr 15;11(4):e0151299. doi: 10.1371/journal.pone.0151299. eCollection 2016.

9.

Transitive inference deficits in unaffected biological relatives of schizophrenia patients.

Onwuameze OE, Titone D, Ho BC.

Schizophr Res. 2016 Aug;175(1-3):64-71. doi: 10.1016/j.schres.2016.02.015. Epub 2016 Apr 3.

PMID:
27050477
10.

Semi-metric analysis of the functional brain network: Relationship with familial risk for psychotic disorder.

Peeters S, Simas T, Suckling J, Gronenschild E, Patel A, Habets P, van Os J, Marcelis M; for Genetic Risk and Outcome of Psychosis (G.R.O.U.P.).

Neuroimage Clin. 2015 Oct 9;9:607-16. doi: 10.1016/j.nicl.2015.10.003. eCollection 2015.

11.

Familiality of Psychotic Disorders: A Polynosologic Study in Multiplex Families.

Peralta V, Goldberg X, Ribeiro M, Sanchez-Torres AM, Fañanás L, Cuesta MJ.

Schizophr Bull. 2016 Jul;42(4):975-83. doi: 10.1093/schbul/sbv192. Epub 2015 Dec 26.

PMID:
26707865
12.

Simvastatin augmentation for recent-onset psychotic disorder: A study protocol.

Begemann MJ, Schutte MJ, Slot MI, Doorduin J, Bakker PR, van Haren NE, Sommer IE.

BBA Clin. 2015 Jul 3;4:52-58. eCollection 2015 Dec.

13.

Structural Brain Network Disturbances in the Psychosis Spectrum.

van Dellen E, Bohlken MM, Draaisma L, Tewarie PK, van Lutterveld R, Mandl R, Stam CJ, Sommer IE.

Schizophr Bull. 2016 May;42(3):782-9. doi: 10.1093/schbul/sbv178. Epub 2015 Dec 6.

PMID:
26644605
14.

Levels of Red Blood Cell Fatty Acids in Patients With Psychosis, Their Unaffected Siblings, and Healthy Controls.

Medema S, Mocking RJ, Koeter MW, Vaz FM, Meijer C, de Haan L, van Beveren NJ; GROUP;Genetic Risk and Outcome of Psychosis investigators, Kahn R, de Haan L, van Os J, Wiersma D, Bruggeman R, Cahn W, Meijer C, Myin-Germeys I.

Schizophr Bull. 2016 Mar;42(2):358-68. doi: 10.1093/schbul/sbv133. Epub 2015 Sep 18.

PMID:
26385764
15.

Further Evidence That Cannabis Moderates Familial Correlation of Psychosis-Related Experiences.

van Winkel R; GROUP Investigators.

PLoS One. 2015 Sep 18;10(9):e0137625. doi: 10.1371/journal.pone.0137625. eCollection 2015.

16.

The association of DNA methylation and brain volume in healthy individuals and schizophrenia patients.

Liu J, Siyahhan Julnes P, Chen J, Ehrlich S, Walton E, Calhoun VD.

Schizophr Res. 2015 Dec;169(1-3):447-52. doi: 10.1016/j.schres.2015.08.035. Epub 2015 Sep 14.

PMID:
26381449
17.

Brain structure and function correlates of cognitive subtypes in schizophrenia.

Geisler D, Walton E, Naylor M, Roessner V, Lim KO, Charles Schulz S, Gollub RL, Calhoun VD, Sponheim SR, Ehrlich S.

Psychiatry Res. 2015 Oct 30;234(1):74-83. doi: 10.1016/j.pscychresns.2015.08.008. Epub 2015 Aug 21.

PMID:
26341950
18.

Bone Mineral Density as a Marker of Cumulative Estrogen Exposure in Psychotic Disorder: A 3 Year Follow-Up Study.

van der Leeuw C, Peeters S, Domen P, van Kroonenburgh M, van Os J, Marcelis M; Genetic Risk and Outcome in Psychosis (G.R.O.U.P.).

PLoS One. 2015 Aug 26;10(8):e0136320. doi: 10.1371/journal.pone.0136320. eCollection 2015.

19.

Structural MRI Differences between Patients with and without First Rank Symptoms: A Delusion?

Heering HD, Koevoets GJ, Koenders L, Machielsen MW, Meijer CJ, Kubota M, de Nijs J, Cahn W, Hulshoff Pol HE, de Haan L, Kahn RS, van Haren NE.

Front Psychiatry. 2015 Jul 29;6:107. doi: 10.3389/fpsyt.2015.00107. eCollection 2015.

20.

Specificity of Incident Diagnostic Outcomes in Patients at Clinical High Risk for Psychosis.

Webb JR, Addington J, Perkins DO, Bearden CE, Cadenhead KS, Cannon TD, Cornblatt BA, Heinssen RK, Seidman LJ, Tarbox SI, Tsuang MT, Walker EF, McGlashan TH, Woods SW.

Schizophr Bull. 2015 Sep;41(5):1066-75. doi: 10.1093/schbul/sbv091.

PMID:
26272875
Items per page

Supplemental Content

Write to the Help Desk